These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 37132470)
41. Hidradenitis suppurativa and inflammatory bowel disease in a nested case-control study. Neri B; Mossa M; Salvatori S; Appolloni V; Pensa C; Lambiase S; Lolli E; Calabrese E; Monteleone G; Bianchi L; Campione E; Biancone L Dig Liver Dis; 2023 Apr; 55(4):490-495. PubMed ID: 36371384 [TBL] [Abstract][Full Text] [Related]
42. Severity and Area Score for Hidradenitis (SASH): a novel outcome measurement for hidradenitis suppurativa. Kirby JS; Butt M; King T Br J Dermatol; 2020 Apr; 182(4):940-948. PubMed ID: 31233623 [TBL] [Abstract][Full Text] [Related]
43. Evaluation of Hidradenitis Suppurativa Disease Course During Pregnancy and Postpartum. Lyons AB; Peacock A; McKenzie SA; Jacobsen G; Naik HB; Shi VY; Hamzavi IH; Hsiao JL JAMA Dermatol; 2020 Jun; 156(6):681-685. PubMed ID: 32347884 [TBL] [Abstract][Full Text] [Related]
44. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa. Miller I; Lynggaard CD; Lophaven S; Zachariae C; Dufour DN; Jemec GB Br J Dermatol; 2011 Aug; 165(2):391-8. PubMed ID: 21457202 [TBL] [Abstract][Full Text] [Related]
45. Guselkumab for hidradenitis suppurativa: a phase II, open-label, mode-of-action study. Dudink K; Bouwman K; Chen Y; DePrimo SE; Munoz-Elias EJ; Aarts P; Schappin R; Florencia EF; van Heeswijk B; Prens LM; van der Zee HH; Prens EP; van Straalen KR; Horváth B Br J Dermatol; 2023 Apr; 188(5):601-609. PubMed ID: 36811949 [TBL] [Abstract][Full Text] [Related]
46. Potential Benefits of the Mediterranean Diet and Physical Activity in Patients with Hidradenitis Suppurativa: A Cross-Sectional Study in a Spanish Population. Lorite-Fuentes I; Montero-Vilchez T; Arias-Santiago S; Molina-Leyva A Nutrients; 2022 Jan; 14(3):. PubMed ID: 35276909 [TBL] [Abstract][Full Text] [Related]
48. The Broad-Spectrum Impact of Hidradenitis Suppurativa on Quality of Life: A Comparison with Psoriasis. Sampogna F; Fania L; Mazzanti C; Caggiati A; Pallotta S; Panebianco A; Mastroeni S; Didona B; Pintori G; Abeni D Dermatology; 2019; 235(4):308-314. PubMed ID: 31121589 [TBL] [Abstract][Full Text] [Related]
49. [Impact of LAight therapy on hidradenitis suppurativa care]. Zimmer S; Basien K; von Stebut E Hautarzt; 2021 Jul; 72(7):586-594. PubMed ID: 34125251 [TBL] [Abstract][Full Text] [Related]
50. Self-management-competency as a new target in Hidradenitis suppurativa care. Mann C; Staubach P; Grabbe S; Wegner J; Hennig K; Nikolakis G; Szepietowski JC; Matusiak L; von Stebut E; Kirschner U; Podda M; Garcovich S; Schultheis M J Dermatolog Treat; 2023 Dec; 34(1):2245082. PubMed ID: 37577779 [No Abstract] [Full Text] [Related]
51. New treatments and new assessment instruments for Hidradenitis suppurativa. van Straalen KR; Ingram JR; Augustin M; Zouboulis CC Exp Dermatol; 2022 Sep; 31 Suppl 1(Suppl 1):33-39. PubMed ID: 35582833 [TBL] [Abstract][Full Text] [Related]
52. Clinical selection criteria in new clinical trials of hidradenitis suppurativa: External validity and implications on the daily clinical practice. Montero-Vilchez T; Salvador-Rodriguez L; Sanchez-Diaz M; Cuenca-Barrales C; Martinez-Lopez A; Arias-Santiago S; Molina-Leyva A Dermatol Ther; 2020 Nov; 33(6):e14254. PubMed ID: 32860480 [TBL] [Abstract][Full Text] [Related]
53. Vascularization and fibrosis are important ultrasonographic tools for assessing response to adalimumab in hidradenitis suppurativa: Prospective study of 32 patients. Nazzaro G; Calzari P; Passoni E; Vaienti S; Moltrasio C; Barbareschi M; Muratori S; Veraldi S; Marzano AV Dermatol Ther; 2021 Jan; 34(1):e14706. PubMed ID: 33368976 [TBL] [Abstract][Full Text] [Related]
54. The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study. Rivera-Díaz R; Pozo T; Alfageme F; Díaz Ley B; Osorio GF; Chico R; Vilarrasa E; Silvente C; Ciudad Blanco C; Romaní J; Martorell A; Fernández P; Romero Ferreiro C; Molina Leyva A Actas Dermosifiliogr; 2023 Oct; 114(9):T755-T762. PubMed ID: 37479135 [TBL] [Abstract][Full Text] [Related]
55. The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study. Rivera-Díaz R; Pozo T; Alfageme F; Díaz Ley B; Osorio GF; Chico R; Vilarrasa E; Silvente C; Ciudad Blanco C; Romaní J; Martorell A; Fernández P; Romero Ferreiro C; Molina Leyva A Actas Dermosifiliogr; 2023 Oct; 114(9):755-762. PubMed ID: 37331620 [TBL] [Abstract][Full Text] [Related]
57. Low Utilization of the Dermatology Ambulatory Encounter among Patients with Hidradenitis Suppurativa: A Population-Based Retrospective Cohort Analysis in the USA. Garg A; Lavian J; Strunk A Dermatology; 2017; 233(5):396-398. PubMed ID: 28954266 [TBL] [Abstract][Full Text] [Related]